SF1670 is primarily used in research settings as a selective inhibitor of the PI3K/Akt signaling pathway, particularly targeting the p110δ isoform of phosphoinositide 3-kinase (PI3K). This makes it a valuable tool in studies related to immune cell function, as p110δ is highly expressed in leukocytes and plays a key role in lymphocyte activation and proliferation. It is commonly applied in immunology and oncology research to investigate the role of PI3K signaling in autoimmune diseases, inflammation, and hematological cancers such as leukemia and lymphoma. Due to its specificity, SF1670 helps researchers dissect pathway contributions without broadly affecting other PI3K isoforms, allowing for more precise mechanistic insights. It is not used clinically but serves as a critical compound in preclinical studies aiming to develop targeted therapies.